Amphastar Pharmaceuticals, Inc.
Amphastar Pharmaceuticals, Inc. (AMPH): 19 pipeline candidates · ~21 mo cash runway · 2 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
20.6 months
4% dilution
Lead: Approved
19 candidates
N/A
N/A
A transparent, data-derived signal for Amphastar Pharmaceuticals, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$855.8M
Cash
$171.2M
Quarterly Burn
$56.7M
Runway
20.6 mo
Revenue
$171.2M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (19 candidates)
| Drug | Phase |
|---|---|
| AMP-004 | Phase 2/Phase 3 |
| AMP-004m | Phase 2/Phase 3 |
| AMP-005 | — |
| AMP-025 | — |
| baqsimi | Approved |
| enoxaparin | Approved |
| ganirelix | Approved |
| i004 | Phase 2/Phase 3 |
| Insulin Aspart (AMP-004) | Phase 2/Phase 3 |
| Insulin Degludec (AMP-025) | — |
Showing 10 of 19 candidates. Sign up for full pipeline.
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
213
Total value held
$639.4M
| Holder | Shares | Value |
|---|---|---|
| blackrock, inc. | 5,421,343 | $106.2M |
| vanguard capital management llc | 3,087,310 | $60.5M |
| dimensional fund advisors lp | 2,027,947 | $39.7M |
| state street corp | 1,607,515 | $31.5M |
| td asset management inc | 1,541,044 | $30.2M |
| fuller & thaler asset management, inc. | 1,395,139 | $27.3M |
| marshall wace, llp | 1,025,640 | $20.1M |
| american century companies inc | 1,017,538 | $19.9M |
| geode capital management, llc | 976,650 | $19.1M |
| boston trust walden corp | 944,789 | $18.5M |
Showing top 10 of 213 institutional holders of Amphastar Pharmaceuticals, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Amphastar Pharmaceuticals, Inc.'s pipeline?
Amphastar Pharmaceuticals, Inc. (AMPH) has 19 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Amphastar Pharmaceuticals, Inc.'s lead drug candidate?
Amphastar Pharmaceuticals, Inc.'s most advanced tracked candidate is AMP-004 (Phase 2/Phase 3) for Diabetes care (insulin therapy).
What is Amphastar Pharmaceuticals, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Amphastar Pharmaceuticals, Inc. has approximately 20.6 months of cash runway.
What is Amphastar Pharmaceuticals, Inc.'s market capitalization?
Amphastar Pharmaceuticals, Inc.'s market capitalization is approximately $855.8M.
Who is the CEO of Amphastar Pharmaceuticals, Inc.?
Dr. Yongfeng Zhang Ph.D. is the chief executive officer of Amphastar Pharmaceuticals, Inc. (AMPH).
Get the full picture on Amphastar Pharmaceuticals, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.